Ryan Kolb
Has grant
Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Combining Angiopoietin-like 4 targeted therapy and immune checkpoint inhibitors in obesity-driven breast cancer progression
Open Date: 2022-09-01
Close Date: 2023-09-01
Grant: Close
Targeting ANGPTL4 in obesity-driven breast cancer progression
Open Date: 2020-03-01
Close Date: 2023-02-28
Grant: Close
Modulating Cancer Genetics for Immune Regulation and Breast Cancer Therapy
Open Date: 2019-04-01
Close Date: 2023-03-31
Grant: Close
CD177 suppresses breast-cancer development by inhibiting beta-catenin
Open Date: 2019-03-14
Close Date: 2022-06-30
Grant: Close
Obesity, inflammation and breast cancer
Open Date: 2015-12-07
Close Date: 2021-11-30
Articles (14)
Single-cell RNA sequencing (scRNA-seq) enables high-resolution profiling of immune heterogeneity. Although previous studies have mapped the single-cell transcriptomic atlases of peripheral leukocytes in healthy dogs, the identification and functional characterization of distinct immune subsets remain incomplete. We constructed a single-cell atlas of peripheral leukocytes from six healthy small-breed dogs using the 10x Genomics platform and the updated canFam4 genome. Analysis of 30,040 high-quality transcriptomes revealed 51 distinct immune subsets, including CD14 □ CD33 □ monocytes, XCR1 □ CD1D □ dendritic cells, CEACAM1 □ CD24 □ neutrophils, and IL32 □ BATF □ regulatory T cells, which were underrepresented in canFam3.1-based studies. Interferon-enriched CD14 □ monocytes and CD4 □ T subsets associated with myxomatous mitral valve disease were also identified. Functional analysis revealed that PDCD1 attenuates TCR signaling, LAG3 modulates malate metabolism in CD4 □ T cells, and suppresses TBX21 in CD8 □ T cells associated with viral response. CD274 encoding PD-L1 was linked to IL-10 production in neutrophils, and CTLA4 represented an initial activation of double-negative T subsets. T cell exhaustion scores and proliferative fractions varied across cohorts, reflecting differences in environmental antigenic exposures. Our study represents the first comprehensive, gene-resolved single-cell analysis that reveals immunoregulatory checkpoint mechanisms underlying immune homeostasis in healthy dogs. Our dataset will serve as a valuable resource for future comparative and translational immunology research in dogs.
Year:
2025
Renal cell carcinoma (RCC), the most common form of kidney cancer, is a heterogeneous disease with clear cell RCC (ccRCC) being the most prevalent and aggressive subtype. While most ccRCC tumors have elevated expression of angiopoietin- like 4 ( ANGPTL4 ), in our study we identified a significant subset of patients whose cancers show no increase in ANGPTL4 expression. These patients have a worse prognosis compared to the patients with high expression of ANGPTL4 . These ANGPTL4 -low cancers are characterized by the increased frequency of wild-type Von Hippel- Lindau (WT VHL ), a gene that is commonly mutated in ccRCC, and an enrichment for genes associated with lipid metabolism. Using RCC tumor models with WT VHL, we demonstrate that ANGPTL4 behaves as a tumor suppressor. The loss of ANGPTL4 in ccRCC cell lines results in increased tumor growth and colony formation in a lysosomal acid lipase (LAL)-dependent manner, a phenotype rescued by the expression of N-terminus ANGPTL4. At the mechanistic level, the loss of ANGPTL4 increases LAL activity in ccRCC cells. These data suggest that ANGPTL4 enacts its tumor-suppressive effects in ccRCC by regulating LAL activity. Importantly, the identified patient cohort with low ANGPTL4 expression may exhibit increased reliance on lipid metabolism, which can be a point of target for future therapy. Significance: Our data indicate angiopoietin-like 4 (ANGPTL4) acts as a tumor suppressor in clear cell renal cell carcinoma via regulating lipid metabolism and identifies a cohort of patients with lower expression of ANGPTL4 that are correlated with shorter survival.
Year:
2025
ANGPTL4 suppresses tumor growth of RCC cells with wild-type VHL. A, Graph depicts expression of ANGPTL4 in CAKi-1 WT or A4KO cells relative to PPIA as a fold change compared to WT. B, 2 × 10 6 of the indicated CAKi-1 cells were implanted into the flank of NOD-SCID/IL2RG (NSG) mice. Graph depicts the average tumor volume ± SEM. Two-way ANOVA was done to determine significance ( n = 8 for both groups). C, Renca mouse RCC cells were stably selected for expression of human ANGPTL4-V5. Immunoblot for V5 in the indicated Renca cells. D, Renca or Renca cells expressing human ANGPTL4-V5 (Renca-A4) from ( C ) were implanted into the mammary gland of Balb/C mice. Graph depicts the average tumor volume ± SEM. Two-way ANOVA was done to determine significance ( n = 8 WT, n = 7 Renca-A4). E, 5 × 10 6 of CAKi-1 cells were implanted into the flank of NSG mice. CAKi-1 tumor–bearing mice were treated with 200 μg anti-cANGPTL4 antibody or rat IgG isotype control twice weekly starting at day 14. Graph depicts the average tumor volume ± SEM. F, Graph depicts the number of CD31 + /CD34 + endothelial cells ± SD as a % of single cells from the indicated tumor from ( B ). Welch’s t test was done to determine significance. G, Tumor sections from the indicated tumors in B, were stained for CD31. Graph depicts the average CD31 + staining as a % of total area ± SD. At least three images from three samples were used for each group. Welch’s t test was done to determine significance.
Year:
2024
ANGPTL4 suppresses tumor growth of RCC cells with wild-type VHL. A, Graph depicts expression of ANGPTL4 in CAKi-1 WT or A4KO cells relative to PPIA as a fold change compared to WT. B, 2 × 10 6 of the indicated CAKi-1 cells were implanted into the flank of NOD-SCID/IL2RG (NSG) mice. Graph depicts the average tumor volume ± SEM. Two-way ANOVA was done to determine significance ( n = 8 for both groups). C, Renca mouse RCC cells were stably selected for expression of human ANGPTL4-V5. Immunoblot for V5 in the indicated Renca cells. D, Renca or Renca cells expressing human ANGPTL4-V5 (Renca-A4) from ( C ) were implanted into the mammary gland of Balb/C mice. Graph depicts the average tumor volume ± SEM. Two-way ANOVA was done to determine significance ( n = 8 WT, n = 7 Renca-A4). E, 5 × 10 6 of CAKi-1 cells were implanted into the flank of NSG mice. CAKi-1 tumor–bearing mice were treated with 200 μg anti-cANGPTL4 antibody or rat IgG isotype control twice weekly starting at day 14. Graph depicts the average tumor volume ± SEM. F, Graph depicts the number of CD31 + /CD34 + endothelial cells ± SD as a % of single cells from the indicated tumor from ( B ). Welch’s t test was done to determine significance. G, Tumor sections from the indicated tumors in B, were stained for CD31. Graph depicts the average CD31 + staining as a % of total area ± SD. At least three images from three samples were used for each group. Welch’s t test was done to determine significance.
Year:
2024
Subset of patients with ccRCC with low expression of ANGPTL4 is associated with shorter survival and lipid metabolism. A, ANGPTL4 expression in the indicated cancer types. Data generated from TCGA pan-cancer normalized RNAseq data generated using the Human Protein Atlas. B, ANGPTL4 mRNA expression in TCGA ccRCC samples compared to normal kidney tissue samples. C, ANGPTL4 expression in the indicated human ccRCC cell lines or immortalized human proximal tubule cells (HK-2) relative to GAPDH . D, Distribution of ANGPTL4 mRNA levels in TCGA ccRCC (KIRC) samples. Graph depicts the number of samples within the indicated robust Z -score range. A subset of patients with significantly lower ANGPTL4 expression (robust Z -score ≤ −3.5) is indicated as ANGPTL4 -low distinguishable from the rest of the samples labeled as bulk samples. E, Kaplan–Meier curve depicting overall survival (OS) of ccRCC samples with low expression of ANGPTL4 compared to the rest of the sample. F, GSEA of TCGA samples comparing ANGPTL4 -low (robust Z ≤ −3.5) and bulk samples (robust Z > −3.5). Graph depicts the nominal enrichment score (NES) of indicated gene sets enriched in the indicated group. The FDR is indicated. G and H, Enrichment plot for the indicated gene set from the GSEA in F .
Year:
2024
Renal cell carcinoma (RCC), the most common form of kidney cancer, is a heterogeneous disease with clear cell RCC (ccRCC) being the most prevalent and aggressive subtype. While most ccRCC tumors have elevated expression of angiopoietin- like 4 ( ANGPTL4 ), in our study we identified a significant subset of patients whose cancers show no increase in ANGPTL4 expression. These patients have a worse prognosis compared to the patients with high expression of ANGPTL4 . These ANGPTL4 -low cancers are characterized by the increased frequency of wild-type Von Hippel- Lindau (WT VHL ), a gene that is commonly mutated in ccRCC, and an enrichment for genes associated with lipid metabolism. Using RCC tumor models with WT VHL, we demonstrate that ANGPTL4 behaves as a tumor suppressor. The loss of ANGPTL4 in ccRCC cell lines results in increased tumor growth and colony formation in a lysosomal acid lipase (LAL)-dependent manner, a phenotype rescued by the expression of N-terminus ANGPTL4. At the mechanistic level, the loss of ANGPTL4 increases LAL activity in ccRCC cells. These data suggest that ANGPTL4 enacts its tumor-suppressive effects in ccRCC by regulating LAL activity. Importantly, the identified patient cohort with low ANGPTL4 expression may exhibit increased reliance on lipid metabolism, which can be a point of target for future therapy. Significance: Our data indicate angiopoietin-like 4 (ANGPTL4) acts as a tumor suppressor in clear cell renal cell carcinoma via regulating lipid metabolism and identifies a cohort of patients with lower expression of ANGPTL4 that are correlated with shorter survival.
Year:
2024
Loss of ANGPTL4 is associated with enrichment for lipid metabolism genes. A, Volcano plot for CAKi1 A4KO versus WT cells. Genes with an absolute value log 2 fold change ≥1 and an adjusted P value of ≤0.05 are indicated. Genes upregulated in A4 KO cells are red and genes downregulated in A4KO cells are blue. B, GSEA was performed for CAKi-1 A4KO and WT cells. Graph depicts the nominal enrichment score (NES) of gene sets related to metabolism that were enriched—had a FDR P value is indicated by the heat bar. Gray bars had a nominal P value that was lower than the threshold for the package used and thus had a value of 0. C, Enrichment plot for the indicated gene set from the GSEA analysis in B . The FDR and nominal P value are indicated. D, Heatmap of the genes in the gene set from C, for CAKi-1 A4KO and WT cells. E, GSEA analysis was performed for 786O A4KO and WT cells. Enrichment plot for the indicated gene set showing enrichment in A4KO cells. The FDR and nominal P value are indicated. F, Graphs depict the average mRNA expression relative to PPIA of the indicated genes in CAKi-1 WT and A4KO cells ± SD. Welch’s t test was done to determine significance.
Year:
2024
nANGPTL4 suppresses ccRCC colony formation. A, MTS assay of the indicated CAKi-1 cells. Graph depicts the average absorbance ± SD. Two-way ANOVA was done to determine significance ( n = 6 all groups). B, The indicated 786O cells were incubated with CSFE and analyzed by flow cytometry. The graph depicts the average % proliferation of the cells ± SD. Welch’s t test was done to determine significance. C, Soft agar colony assay. The indicated CAKi-1 cells were cultured on soft agar for 30 days and the number of colonies per well was counted. Left: representative images of colonies from the indicated cells (10× magnification). Right: graph depicts the average number of colonies ± SD. Welch’s t test was used to determine significance. D, The indicated RCC4 cell line was incubated in nonadherent conditions for 72 hours. The graph depicts the average number of colonies/well ± SD. Welch’s t test was done to determine significance. E, Graph depicts the average number of colonies/well of the indicated CAKi-1 cells treated as indicated with rat IgG or anti-cANGPTL4 ± SD. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. F, Graph depicts the average number of colonies per well ± SD. of CAKi-1 A4 KO cells transfected with full length (FL), N-terminus or mock transfected as indicated. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. G, Graph depicts the average number of colonies/well of the indicated 786O cells ± SD. Welch’s t test was done to determine significance. H, Graph depicts the average number of colonies/well ± SD of 786O A4 KO cells transfected with N-terminus or mock transfected as indicated. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance.
Year:
2024
Subset of patients with ccRCC with low expression of ANGPTL4 is associated with shorter survival and lipid metabolism. A, ANGPTL4 expression in the indicated cancer types. Data generated from TCGA pan-cancer normalized RNAseq data generated using the Human Protein Atlas. B, ANGPTL4 mRNA expression in TCGA ccRCC samples compared to normal kidney tissue samples. C, ANGPTL4 expression in the indicated human ccRCC cell lines or immortalized human proximal tubule cells (HK-2) relative to GAPDH . D, Distribution of ANGPTL4 mRNA levels in TCGA ccRCC (KIRC) samples. Graph depicts the number of samples within the indicated robust Z -score range. A subset of patients with significantly lower ANGPTL4 expression (robust Z -score ≤ −3.5) is indicated as ANGPTL4 -low distinguishable from the rest of the samples labeled as bulk samples. E, Kaplan–Meier curve depicting overall survival (OS) of ccRCC samples with low expression of ANGPTL4 compared to the rest of the sample. F, GSEA of TCGA samples comparing ANGPTL4 -low (robust Z ≤ −3.5) and bulk samples (robust Z > −3.5). Graph depicts the nominal enrichment score (NES) of indicated gene sets enriched in the indicated group. The FDR is indicated. G and H, Enrichment plot for the indicated gene set from the GSEA in F .
Year:
2024
nANGPTL4 inhibits LAL to suppress ccRCC colony formation. A–C, Total intracellular lipids in the indicated CAKi-1 or 786O cells were stained with BODIPY 493/503 and the median fluorescence intensity (MFI) was determined. A, Representative histogram is presented for BODIPY staining of CAKi WT (gray) and A4KO (red) cells. B and C, Graph depicts the average BODIPY 493/503 MFI of the indicated CAKi-1 ( B ) and 786O ( C ) cells ± SD. Welch’s t test was used to determine significance. D, CAKi-1 WT and A4KO cells were incubated with BODIPY FL C12 and analyzed by flow cytometry to measure lipid uptake. Left: representative histogram showing BODIPY FL C12 fluorescent intensity of WT (gray) and A4KO (red) cells. Right: graph depicts the average BODIPY FL C12 MFI ± SD in the indicated 786O cells. Welch’s t test was done to determine significance. E, LAL activity was determined by incubating the indicated cells with lysolive-green and measuring the fluorescence Intensity by flow cytometry. Left: representative histogram depicting intensity of lysolive-green fluorescence in CAKi-1 WT (gray) and A4KO (red) cells. Right: graph depicts the average lysolive-green MFI as a fold change compared to WT ± SD. Welch’s t test was done to determine significance. F, Graph depicts the average lysolive-green MFI as a fold change compared to WT ± SD. Welch’s t test was done to determine significance. G, CAKi-1 A4KO cells were mock transfected or transfected with full length (FL) or N-terminus (N-term) ANGPTl4 and incubated with lysolive-green. Left representative histrogram depicting lysolive-green fluorescence intensity in the indicated cell lines. The peak fluorescence intensity in mock transfected cells is indicated by the black line. Right: Average lysolive-green MFI as a fold changed compared to mock transfected ± SD. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. H, Graph depicts the average number of colonies/well of the indicated CAKi-1 cells grown in the presence or absence of the LAL inhibitor lalistat 1. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. I, Graph depicts the average number of colonies/well of the indicated 786O cells grown in the presence or absence of the LAL inhibitor lalistat 1. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. J, CAKi-1 A4KO cells were transfected with siRNA targeting LIPA (gene that encodes LAL) or nontargeting control siRNA (−). Cells were plated in non-adherent conditions, cultured for 72 hours and the number of colonies was counted. Top: western blot for LAL at the indicated time point post transfection. GAPDH blot is used as a loading control. Bottom: graph depicts the average number of colonies per well ± SD. Welch’s t test was done to determine significance. K, CAKi-1 A4KO cells were transfected with a lentivirus plasmid containing CRISPR-Cas9 and one of the three guide RNAs targeting LIPA . After selection total lysates were collected and a Western blot for LAL and GAPDH, as a loading control, was done. Arrow indicates LAL band. L, The indicated CAKi-1 cells (A4KO LIPA KO cells are g2 cells from K ) were cultured in nonadherent conditions for 72 hours and the number of colonies was counted. Graph depicts the number of colonies per well ± SD. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance. M, The indicated CAKi-1 cells were cultured for 72 hours, stained with annexin V-FITC and PI and analyzed by flow cytometry. Graph depicts the % of FITC-positive cells as a percentage of single cells ± SD. One-way ANOVA with Dunnett’s test to correct for multiple comparisons was done to determine significance.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (4)
Brandon Davies
Professor
Iowa State University
Nicholas Borcherding
Assistant Professor
University of Washington Medical Center
Youngmin Yun
-
Weizhou Zhang
Vice Chair of Research/Dr. and Mrs. James Robert Spencer Professor of Pathology
University of Florida
Make your next move.
Prepare your application
Review drafts before you send them.